Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion

NCT04617054 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Stopped The study was discontinued early by the Sponsor for business reasons on 06 Dec 2024

Conditions

Solid Tumor

Interventions

DRUG: AB-106

Sponsor

Nuvation Bio Inc.

Collaborators

[object Object]